Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
1.81B
Market cap1.81B
Price-Earnings ratio
-10.25
Price-Earnings ratio-10.25
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
High today
Low today
Low today
Open price
$29.24
Open price$29.24
Volume
0.00
Volume0.00
52 Week high
$40.22
52 Week high$40.22
52 Week low
$11.66
52 Week low$11.66

Stock Snapshot

The current Stoke Therapeutics(STOK) stock price is $29.13, with a market capitalization of 1.81B. The stock trades at a price-to-earnings (P/E) ratio of -10.25.

On 2026-07-15, Stoke Therapeutics(STOK) stock opened at $29.24, reached a high of —, and a low of —.

Stoke Therapeutics(STOK) shares are trading with a volume of 0, against a daily average of 1.04M.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $40.22 and a 52-week low of $11.66.

In the last year, Stoke Therapeutics(STOK) shares hit a 52-week high of $40.22 and a 52-week low of $11.66.

STOK News

TipRanks 2d
Stoke Therapeutics appoints McCauley as Chief Scientific Officer

Stoke Therapeutics (STOK) announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. McCauley most recently served as the President and...

Investing.com 2d
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com

...

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.